NEWS & EVENTS

Catalent today announced the launch of its new OneXpress® service for the integrated development, scale up and manufacturing of new oral solid dosage forms.

Catalent’s clinical supply site in Bathgate has won Scottish Engineering’s ‘Vice President Award 2020,’ recognising its continuous improvement programme in core values including “patient first, customer dedication, people, innovation, integrity and excellence.”

Catalent today welcomed the news from Nocion Therapeutics, Inc., a biopharmaceutical company developing novel small molecule charged sodium channel blockers, that its first patient has been dosed with NOC-100, an inhaled formula of its NTX-1175 small molecule candidate.

Catalent today announced that it has acquired a new manufacturing facility in Bloomington, Indiana, to create a North American center of excellence for early-phase clinical biologics formulation development and drug product fill/finish services.

Catalent today announced that George Buchman, Ph.D., Vice President, Preclinical & Process Development, will present at the World Vaccine Congress, which will take place virtually on Sept. 28 – October 1, 2020.

T-knife and Catalent today announced they have signed an agreement to provide technology transfer and CGMP clinical manufacturing of T-knife’s T1367 T-cell receptor (TCR) program.

Catalent today announced that it will present at the upcoming BioProcess International virtual conference, taking place between Sept. 21 – 25, 2020.

We are proud to announce that Rheincell has GMP certification and Manufacturing Authorization to supply clinical-grade iPSCs and thus, make a meaningful contribution to advancing cell therapies

Catalent today announced that it will lead multiple workshops and exhibit at the upcoming Global Clinical Supplies Group (GCSG) 2020 Global Virtual Conference, which takes place on Sept. 21-25, 2020.